TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8838194
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (800 mg five times daily)
Study: 1497518
Drug: Subconjunctival injections
Normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subconjunctival injections of fluorouracil (4 to 6 injections for 10 days after surgery)
Study: 1497518
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no fluorouracil injections)
Study: 1497518
Drug: Subconjunctival injections
Normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subconjunctival injections of fluorouracil
Study: 30303695
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 100 mg per day for 8 weeks
Study: 30303695
Drug: Placebo (cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cellulose acetate 100 mg per day for 8 weeks)
Study: 22951801
Drug: Psychotherapy program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy program for treatment of co-dependence
Study: 19383224
Drug: Pre-operative oral
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative oral administration of magnesium for 10 days
Study: 19383224
Drug: Intra-operative flush
Normalized name: T8 Keto Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-operative flush infusion of magnesium
Study: 17449998
Drug: Usual PMG
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual PMG treatment
Study: 15223903
Drug: Immunoglobulin doses
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin doses (four doses compared)
Study: 9619936
Drug: Ambulatory chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory chemotherapy
Study: 12652055
Drug: Weekly folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly folic acid supplement (2,800 microg)
Study: 12652055
Drug: Daily folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily folic acid supplement (400 microg)
Study: 11101478
Drug: Polydextrose 12
Normalized name: fructooligosaccharides/polydextrose 12 gram/30 mL ORAL LIQUID IN PACKET (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polydextrose 12 g plus 50 g glucose
Study: 31331572
Drug: Achillea wilhelmsii
Normalized name: Achillea millefolium oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achillea wilhelmsii capsules, twice daily for 4 weeks
Study: 31331572
Drug: Achillea wilhelmsii
Normalized name: Achillea millefolium oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achillea wilhelmsii capsules
Study: 28434633
Drug: Testosterone propionate
Normalized name: Testosterone Propionate
DrugBank: Testosterone propionate (DB01420)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone propionate 1% ointment twice a day for 30 days
Study: 20634190
Drug: IVIG 500
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 500 mg/kg
Study: 16651205
Drug: Testim 1%
Normalized name: Testim 1% Topical Gel
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testim 1% (5 g)
Study: 16651205
Drug: AndroGel 1%
Normalized name: Androgel 1% Transdermal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: AndroGel 1% (5 g)
Study: 8541168
Drug: Encainide or
Normalized name: encainide Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encainide or flecainide treatment
Study: 25533774
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg per day)
Study: 17053058
Drug: Low-power laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-power laser therapy (LPLT)
Study: 16170158
Drug: Dexamethasone (DEXA)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEXA) 8 mg/m2 during induction and DEXA 6 mg/m2 during the intensifications
Study: 16170158
Drug: Prednisolone (PRED)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone (PRED) 60 mg/m2 during induction and PRED 40 mg/m2 during four intensifications in the SR group and three intensifications in the IR group
Study: 11991446
Drug: Alendronate 80
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate 80 mg
Study: 11991446
Drug: Alendronate 160
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate 160 mg
Study: 9473831
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg preoperative dose
Study: 354746
Drug: Co-trimoxazole (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (single dose, intravenous infusion)
Study: 29273261
Drug: Weekly irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly irinotecan at 95 mg/m2 for ∗1∗1 genotype
Study: 29273261
Drug: Weekly irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly irinotecan at 80 mg/m2 for ∗1∗28 genotype
Study: 29273261
Drug: Weekly irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly irinotecan at 80 mg/m2 for ∗1∗1 genotype
Study: 29273261
Drug: Weekly irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly irinotecan at 65 mg/m2 for ∗1∗28 genotype
Study: 29273261
Drug: Weekly irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly irinotecan at 80 mg/m2 and 65 mg/m2
Study: 29273261
Drug: Capecitabine at
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine at 625 mg/m2
Study: 26630417
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (CV)
Study: 1702012
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg tds orally)
Study: 1702012
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg tds orally)
Study: 347876
Drug: Bromperidol (14-23
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromperidol (14-23 mg/day during acute treatment, average maintenance dose approximately 8 mg, total doses from 3-39 mg for up to four months)
Study: 347876
Drug: Bromperidol (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromperidol (acute treatment)
Study: 16455426
Drug: Low-dose anthracycline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose anthracycline (doxorubicin 50-125 mg/m2)
Study: 11505129
Drug: Rapid fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid fat infusion (0.4 x resting energy expenditure over 6 hrs)
Study: 11505129
Drug: Slow fat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow fat infusion (0.4 x resting energy expenditure over 24 hrs)
Study: 9250846
Drug: Enoxaparin (low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (low-molecular-weight heparin) 1 mg/kg body weight, subcutaneously twice daily for 48 hours to 8 days
Study: 9250846
Drug: Unfractionated heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractionated heparin, continuous intravenous administration for 48 hours to 8 days
Study: 7685749
Drug: MOPP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP chemotherapy followed by high-dose (40 Gy) total or subtotal nodal irradiation
Study: 7685749
Drug: MOPP/ABVD chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP/ABVD chemotherapy followed by high-dose (40 Gy) total or subtotal nodal irradiation
Study: 3494461
Drug: Cimetidine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (24 mg/kg/day) for 4 days
Study: 31888928
Drug: NOAC-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOAC-based treatment strategy
Study: 28682187
Drug: Loss-framed message
Normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Loss-framed message emphasizing consequence of not receiving flu vaccine
Study: 28682187
Drug: Loss-framed message
Normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Loss-framed message emphasizing consequence of receiving flu vaccine
Study: 26138866
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg retosiban
Study: 26138866
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg retosiban
Study: 23828160
Drug: Olanzapine/Reboxetine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine/Reboxetine (4 mg BID)
Study: 18304693
Drug: Nesiritide plus
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nesiritide plus protocol-specified standard therapy
Study: 16565626
Drug: Chan‐Chuang qi‐gong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chan‐Chuang qi‐gong therapy for 21 days
Study: 15194373
Drug: No-antibody induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-antibody induction
Study: 10856733
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 g/day) added to therapy in group I (n=31)
Study: 10856733
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group II, n=20) without L-carnitine
Study: 9062490
Drug: Acipimox (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (oral administration during the last 8 hours)
Study: 3518499
Drug: Women told
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women told they would be tested for marijuana, alcohol, and other drugs
Study: 29657206
Drug: Low-dose intradermal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intradermal (ID) route: 10 μg of vaccine weekly for 8 weeks (total 40 μg)
Study: 29657206
Drug: High-dose intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intradermal (ID) route: 40 μg of vaccine at 1-month intervals (total 80 μg)
Study: 22821660
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy combined with placebo (Control)
Study: 9236561
Drug: Nefopam hydrochloride,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam hydrochloride, 0.3 mg/kg
Study: 9236561
Drug: Meperidine hydrochloride,
Normalized name: Meperidine Hydrochloride, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine hydrochloride, 0.7 mg/kg
Study: 18294333
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg single dose in CYP2C19*17/*17 subjects
Study: 18294333
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg single dose in CYP2C19*1/*1 subjects
Study: 12517462
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (local anaesthetics)
Study: 8706775
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg daily for 2 weeks
Study: 8706775
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg for 1 week
Study: 8706775
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg for 1 week
Study: 25923045
Drug: Remifentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil at three target‐site concentrations: 1, 2, and 3 ng/ml
Study: 25923045
Drug: Naloxone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (6 μg/kg bolus followed by 0.1 μg/kg/min infusion)
Study: 25923045
Drug: Remifentanil before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil before and after metoclopramide administration
Study: 20647058
Drug: Improved medication
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved medication labels
Study: 17470735
Drug: 2% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% testosterone in Vanicream (10 mg daily)
Study: 12575232
Drug: nao-yi-an treatment
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nao-yi-an treatment
Study: 12575232
Drug: medicine control
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: medicine control group
Study: 10319667
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (amoxycillin 500 mg t.i.d., metronidazole 500 mg t.i.d., furoxone 100 mg t.i.d. for 5 days during the 3rd week) + ranitidine 300 mg daily for 8 weeks
Study: 10319667
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg daily for 12 months
Study: 7635369
Drug: Lymphocyte immunotherapy
Normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphocyte immunotherapy (LI) + Progesterone (P)
Study: 2793265
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg) plus Nifedipine (10 mg)
Study: 694487
Drug: Antibiotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics plus granulocyte transfusions (1.7‐14.7 X 10(10) granulocytes by 1‐5 daily transfusions, mean 6.6 X 10(10))
Study: 30829619
Drug: GDNF (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDNF (administered every 4 weeks for 80 weeks)
Study: 26130141
Drug: 48 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 48 weeks of Peginterferon (Peg‐IFN) alfa‐2a 180 μg/week plus weight-based ribavirin (RBV) 1,000‐1,200 mg/day
Study: 26130141
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of Peginterferon (Peg‐IFN) alfa‐2a 180 μg/week plus weight-based ribavirin (RBV) 1,000‐1,200 mg/day
Study: 16676701
Drug: Caffeine ingestion
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine ingestion (6 mg/kg body mass)
Study: 10945318
Drug: RIG200 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIG200 (6 nmol/min infusion)
Study: 10945318
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (0.06 nmol/min infusion)
Study: 2943050
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ipratropium bromide (200 micrograms three times daily for four weeks)
Study: 2943050
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ipratropium bromide
Study: 29387936
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioral therapy (CBT) for insomnia
Study: 23076383
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of 10-valent pneumococcal conjugate vaccine (PHiD-CV) and tetravalent meningococcal conjugate vaccine (MenACWY-TT)
Study: 16627574
Drug: 7 mg
Normalized name: pectin 7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg transdermal nicotine patch (NIC)
Study: 11045912
Drug: Sildenafil (Viagra)
Normalized name: sildenafil Oral Tablet [Viagra]
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil (Viagra) 10-100 mg, taken as needed approximately 1 hour prior to sexual activity
Study: 9193208
Drug: Tizanidine hydrochloride
Normalized name: Tizanidine Hydrochloride
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tizanidine hydrochloride (8 or 16 mg)
Study: 1553900
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus epirubicin (60 mg/m2 cisplatin + 75 mg/m2 epirubicin)
Study: 1553900
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus doxorubicin (60 mg/m2 cisplatin + 60 mg/m2 doxorubicin)
Study: 27445468
Drug: TIO 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIO 18 µg
Study: 20872225
Drug: Pueraria mirifica
Normalized name: PUERARIA MIRIFICA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pueraria mirifica 25 mg
Study: 20872225
Drug: Pueraria mirifica
Normalized name: PUERARIA MIRIFICA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pueraria mirifica 50 mg
Study: 17448262
Drug: Oral progestogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral progestogens
Study: 12357478
Drug: Budesonide/formoterol 80/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 80/4.5 microg, two inhalations twice daily (n = 148)
Study: 12357478
Drug: Budesonide 100
Normalized name: budesonide 100 MCG/ACTUAT Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 100 microg, two inhalations twice daily (n = 138)
Study: 3135194
Drug: Flumazenil 0.1
Normalized name: flumazenil 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil 0.1 mg.kg‐1
Study: 3135194
Drug: Flumazenil 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil 0.2 mg.kg‐1
Study: 11762152
Drug: Oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormone replacement therapy (n = 19)
Study: 11762152
Drug: Transdermal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormone replacement therapy (n = 18)
Study: 11762152
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of oral vs transdermal hormone replacement therapy
Study: 9407675
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg (2 x ED90)
Study: 9407675
Drug: Vecuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.1 mg/kg (2 x ED90)
Study: 8498661
Drug: Intravenous sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sufentanil (SIV)
Study: 20653677
Drug: Ciclosporin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin (5 mg kg(‐1))
Study: 16960164
Drug: Test meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test meal containing 50 g fat
Study: 15275751
Drug: ATC dosing
Normalized name: ATCH (1-24)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATC dosing of acetaminophen with codeine (120 mg/12 mg/5 ml) every 4 h for 3 days
Study: 15275751
Drug: PRN dosing
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRN dosing of acetaminophen with codeine (120 mg/12 mg/5 ml) every 4 h PRN for 3 days
Study: 15275751
Drug: ATC dosing
Normalized name: ATCH (1-24)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATC dosing of acetaminophen with codeine with nurse coaching (120 mg/12 mg/5 ml) every 4 h for 3 days
Study: 8495774
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of intranasal nafarelin
Study: 8495774
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of intranasal nafarelin
Study: 24055212
Drug: Rotigotine 2
Normalized name: ROTIGOTINE 2MG/24HRS PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine 2 mg/24 h
Study: 24055212
Drug: Rotigotine 3
Normalized name: ROTIGOTINE 3MG/24HRS PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine 3 mg/24 h
Study: 19719796
Drug: Motivationally Enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivationally Enhanced (ME) treatment plus Nicotine Replacement Therapy (NRT)
Study: 19719796
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Care (SC) treatment plus Nicotine Replacement Therapy (NRT)
Study: 9389778
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oestradiol (1.0 g Divigel/Sandrena 0.1% gel) applied on a 200 cm2 area
Study: 9389778
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oestradiol (1.0 g Divigel/Sandrena 0.1% gel) applied on a 400 cm2 area
Study: 9389778
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oestradiol (1.0 g Divigel/Sandrena 0.1% gel) applied on the largest possible area
Study: 7958491
Drug: Mild hypoglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild hypoglycemia (6.4, 3.6, and 2.6 mmol/l)
Study: 7958491
Drug: Moderate hypoglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate hypoglycemia (6.4, 3.6, and 2.6 mmol/l)
Study: 22068326
Drug: Pharmacist interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist interventions on antibiotic use
Study: 19783714
Drug: etoricoxib 60
Normalized name: etoricoxib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 60 mg (days 1‐7)
Study: 19783714
Drug: etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 120 mg (days 8‐14)
Study: 19783714
Drug: etoricoxib 90
Normalized name: etoricoxib 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 90 mg (days 1‐7)
Study: 17108342
Drug: Target hemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target hemoglobin value in the normal range (13.0 to 15.0 g per deciliter, group 1)
Study: 17108342
Drug: Subnormal hemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subnormal hemoglobin range (10.5 to 11.5 g per deciliter, group 2)
Study: 1533090
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg oral micronized dehydroepiandrosterone
Study: 1533090
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral micronized dehydroepiandrosterone